DexCom CapEx decreased by 24.8% to $76.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 12.0%, from $87.00M to $76.60M. Over 4 years (FY 2021 to FY 2025), CapEx shows relatively stable performance with a -1.7% CAGR.
An increase often signals growth initiatives and capacity expansion, while a decrease may suggest cost-cutting or a shift toward asset-light strategies.
This metric measures the cash outflows used to acquire, upgrade, and maintain physical assets such as property, building...
Commonly compared as a percentage of revenue; capital-intensive firms like Abbott require consistent investment to remain competitive in medical technology.
capital_expenditures| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $101.20M | $108.10M | $80.20M | $101.60M | $91.50M | $108.20M | $63.50M | $74.70M | $59.00M | $50.40M | $52.50M | $56.90M | $66.10M | $111.20M | $124.60M | $87.00M | $94.10M | $80.50M | $101.90M | $76.60M |
| QoQ Change | — | +6.8% | -25.8% | +26.7% | -9.9% | +18.3% | -41.3% | +17.6% | -21.0% | -14.6% | +4.2% | +8.4% | +16.2% | +68.2% | +12.1% | -30.2% | +8.2% | -14.5% | +26.6% | -24.8% |
| YoY Change | — | — | — | — | -9.6% | +0.1% | -20.8% | -26.5% | -35.5% | -53.4% | -17.3% | -23.8% | +12.0% | +120.6% | +137.3% | +52.9% | +42.4% | -27.6% | -18.2% | -12.0% |